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T he releasc of prostaglandin D z (PGD2), prostaglandin E2 
(PGE2), and histamine induced by antigen and compo und 
48/80 was studied usin g an in vitro model of anaph ylaxis 
in guinea pig skin. Abdominal skin from ovalbumin-sen-
sitized g uinea pigs was cut into 0.5-1.0 mm-thick slices 
w hich were in cubated in Tyrode solutio n at 37°C with o r 
without either ovalbumin o r 48/80. Released PGD2 and 
PGE2 were measured by radioimmunoassay and gas cl1ro-
matography-m ass spectro m etry, respectively. Release of 
PGDz was detectable at 2 min after chall enge (50 j.Lg/ml 
ovalbumin) , reaching a m aximum at about 15 min . His-
tamjne release was more rapid , achieving 50% of m axi-
mum at about 4 min compared to abo ut 7 min for PGD2. 
In 11 experiments incubation with ovalbumin (50 j.Lg/ml 
for 10 tnin) induced a significant 6-fold increase in PGD2 
co mpared to unchallenged controls (399 ± 53 and 67 ± 
P rostaglandin D 2 (PGD2) is the m ajor cyclooxygenase m eta bo lite of arachidon ic acid rel eased b y rat and hu-man m as t cell s following immuno logic challenge [1) . Intraderm al inj ectio n ofPGD2 in the rat causes in creased vascular permeability and in humans produces pro-
longed cutaneous dose-related erythem a [2 /. The release ofPGD2 
from skin in immed iate-hy persensitivity reactions was therefore 
ex plored, as PGD2 m ay contribute either directly o r in synergism 
w ith other m ast cell m ediato rs to the inA ammation produced. 
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19 ng/g dry weight skjn , respectively; m ean ± SEM) and 
a net 47.2% hista mine release. In contrast, a sm aller (27%) 
ri se in PGE2 was found . Indo m ethacin (14 j.Lm) completely 
suppressed evoked PGD2 and PGE2 synthesis without ev-
ident effect on histamine release , suggesting that the release 
of hista mine in this model is no t dependent on prostaglan-
din production . The m ast cell degranulating agent COI11-
pound 48/80 (50 j.Lg/ml) released significant amounts of 
PGDz (340 ± 86 ng/g skin compared to 89 ± 30 ng/g for 
contro l skin , n = 5) but had no appreciable effect o n PGEz. 
These results show that guinea pig skin can synthesize sig-
nifi cant quantities ofPGDz in anaphylactic reactions. Pros-
taglandin D 2 produced in acute allerg ic reactions in skin in 
vivo tnay contribute to the inflam.m ato ry reaction, either 
directl y o r in synergism with other m ediato rs. J It'llJest Der-
Inatol 88: 115-119, 1987 
We used the in vitro m odel of immediate cutaneous hypersen-
sitivity in the guinea pig [3] to study the release ofPGD2 in rclation 
to histamine release. T he m as t cell degranulating agent compound 
48/80 has been shown to release hista mine from guinea pig skin 
(4) . Compound 48/80 was used to compare no nimmunologically 
induced PGD2 and hista mine release with that stimulated by an-
ti gen . Prostaglandin E 2 (PGE2) release was also m easured as an 
indi ca tor of general cyclooxygenase activity . 
MATE RIALS AND M ETH ODS 
Materials Rabbit anti-PGD2 antisera were purchased from Ser-
agen In c, Boston , M assachusetts. [5, 6, 8, 9, 12, 14, 15-3H]PGD2 
(100 C i/ mmo l) was o btained fro m N ew England Nuclea r, U.K. 
Pico-Fluor 30 was purchased fro m Packard Instruments Ltd , Eng-
land . Prostaglandin D 2 , PGE2, com po und 48/80, egg albumin 
(grade II fo r sensiti za tio n of guinea pigs and grade III for antigen 
challenge) were from th e Sig ma C hemi ca l Co., E ngland. His-
tamine dih ydrochloride was from BDH C hemica ls Ltd, E ngland, 
and indom ethacin was fro m M erck Sharp & Dohmc, England. 
/3,3',4,4' -2H)PGE2 was a g ift from Dr J. E. Pike, the Upjohn 
Company, Kalam azoo, Michigan. Sep-Pak C .s extraction ca r-
tridges were from Millipo re Ltd, E ng land . 
Animals Male Dunkin-Hartley g uinea pi gs, weighing approx-
imately 400 g, were sensitized to ova lbumin by s.c. inj ections of 
50 m g into each hind limb and 100 m g i. p . T he ovalbumin fo r 
inj ectio n was prepa red as a 10% soluti on in 0.9% sa line. T he 
guinea pigs were used after an interval of 3 weeks. 
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Skin Incubation Guinea pigs were killed by stunning and 
exsanguination. The shaved abdominal skin was removed, cleaned 
of subcutaneous tissue and cut into 0. 5-1. 0 mm-thick sli ces using 
a hand mi cro tom e. Slices from different areas of skin w ere ran-
domized and washed with ice-cold Tyrode solution w hi ch had 
previously been equilibrated with 5% ca rbon dioxide in oxygen. 
Composition o f T yrode solution (g/liter) was: N aCI 8. 0, KC I 
0.2, MgClz 0 .1, CaCh 0.2, N aHzPO" 0. 05 , N aHC03 1.0, and 
glucose 1.0. 
Aliquo ts of washed skin slices, 0. 7-0.8 g wet weight, were 
distributed in silanized test tubes containing 4.75 ml o f T yrode 
solution held at 2-4°C on ice. Duplica te samples o f skin slices 
were preincubated in a shakin g w ater bath fo r 5 min at 37°C. 
O valbumin o r compound 48/80 w as then added in 0. 25 ml 
Ty rode solution, and the incubation continued fo r a further 10 
min unless stated otherw ise. Buffer alone was added to control 
incubations. Incubations w ere termin ated by rapidl y cooling th e 
tubes in ice and deca ncing the supernatant T yrode solution, except 
in time course ex periments, when th e supern atants w ere decanted 
immediately at each time po int. Supernatant sa mpl es were usuall y 
extracted immediatel y or stored at - 70°C overnight. The re-
m aining skin slices were frozen, then freeze-dried overnight, and 
weighed to give the dry w eight o f skin in each incubation tube. 
The m ean dry weight o f skin per sample w as 0. 135 g. 
Prostaglandin Assays Incuba tion supernatants were equili-
brated w ith 25 ng [3,3' ,4,4' - 2HJPGE2 as internal standard. 
Recovery of PGDz befo re radioimmunoassay was determined 
fro m 2 samples of 5 ml T yrode solution containing 104 dpm 
[3H]PGDz and 5 ng unlabeled PGDz as carrier taken through the 
ex traction and purification procedure. P rostaglandins were ex-
trac ted on C IS Sep-Pak cartridges using the method of Powell [5] 
and the prostaglandins pu rified by hi gh-perfo rmance liquid chro-
m atograph y (HPLC) on a LiC hrosorb Si-60 silica column as pre-
vio usly described [6]. Recovery of [3H]PGDz in the 2 contro l 
samples was 50-60%. 
Prostaglandin E2 wa's assayed by gas chromatograph y-mass 
spectrom etry (GC-MS) as the methyl ester-trimeth ylsi lyl-eno l 
deri va ti ve [7). 
Pros taglandin D2 was determined by radioimmunoassay using 
a m ethod similar to that described by H ennann et al fo r PGF20 [8J. 
B rieRy, sa m ples fo r analysis were dissolved in 0. 5 ml o f 0. 1 M 
tri cine-bu ffered saline. Antisera , at a ti te r of 1/300, and 1.5-2 X 
104 dpm. [3H]PGD 2 were used in a fin al incubation volume of 0 .3 
m1. T he assay tubes were incubated at room temperatu re fo r 30 
min and at 4°C overnight and bound m aterial precipitated by 
addin g 1.4 ml of 65% saturated ammonium sulfate solution con-
taining 35 m g calcium sul fa te in suspension. After centrifu ga tion 
the precipitate was resuspended in 0. 3 ml w ater and counted in 
1.2 m1 Pico- Fluo r 30 to a presenc level o f 104 counts. The cross-
reactivity o f the antiserum at 50% B IB o fo r PGEz, PG F20 , and 
thro mboxane B2 was < 3.0% , <3. 0%, and < 3.5% , respectively, 
w here PGD 2 = 100% (Seragens' data) . 
The assay conditions gave maximum binding fo r e H]PGD 2 of 
around 35% w ith a 50% inhibition of binding by 2.3 ng unlabeled 
PGD z. All calculations o f unknowns were perfo rm ed on the linea r 
po rtion o f the standard curve (80% B IBo- 20% B IBo), w hich 
corresponded to 0.3-11 .0 ng PGD2. 
Histamine Assay T he residual histamine in the skin was re-
leased by res uspending the dried skin slices in boiling T yrode 
solu tion fo r 5 min . T he cooled supernatants were diluted w ith 
T yrode solution and bioassayed fo r histamine using the atropin-
ized guinea pig ileu m . The resul ts w ere expressed as micro grams 
of histamine per g ram dry w eight o f skin. 
In preliminary experiments, the histamine content o f incuba-
tion supernatants was also determined. Summation of the residual 
and supernatant histamine consistently ga ve lower values in an-
ti gen-challenged sa mples compared to the unchallenged samples . 
Previous w ork [9] has shown th at guinea pig skin can metabolize 
histamine. Calculation of the percentage histamine release from 
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the proportion in the supernatant compared to the to tal sampk 
content res ults in a lower apparent value as a consequence o t 
metabolism of th e released histamine. Therefo re, the redu ctiol1 
in histamine content o f th e skin slices w as used as the measure 
o f histamine release and was calculated using the fo rmula: % 
reduction in histamine content = (1 - B I A) X 100, w hen: 
A = hi stamine content o f skin slices preincubated for 5 min only, 
and B = histamine content o f skin slices after the 10-min incu, 
bation w ith or w ithout either ovalbumin o r compound 48/80. 
Both histamine contents were ex pressed as mi crograms per gram 
dry weight o f skin slices. 
Statistics Da ta were analyzed by Students' I-tes t for paired 
sa mples. Values quoted are mean ± SEM. 
RES ULTS 
Identification of PGD2 Extraction and chro matograph y of 
skin supern atants prio r to radi oimmunoassay of PGDz ensured 
that cross-reactivity of the antiserum for o ther cyclooxygenase 
and lipoxygenase metabo lites o f arachidonic acid wo uld not com-
promise the assay. The HPLC system used separated PGD2 from 
PGE2 and o ther m aj o r cyclooxygenase produ cts (Fig 1). About 
73% of the immunoreactive m aterial from 2 antigen-challenged 
skin supernatants cochro matog raphed as a single peak wi th the 
sa me retention time as [3HjPGD2. Authentic PGD 2 subj ected to 
the sam e extraction and HPLC gave a similar immunochro-
matogram . 
Gas chromatography-m ass spectrom etry confirmed the iden-
tify of PG D2 fro m antigen-challenged skin . The frac ti on from 
HPLC containing the immunoreacti ve m aterial coch ro mato-
graphing w ith authentic PGD2 was derivatized as the pen taRuoro-
benzyloxime-trimethylsily lether-meth yl es ter. T he molecular ion 
was observed at m lz 705 with a base peak at mlz 634 ([M-CsHld +). 
O ther maj or ions w ere o bse rved at m lz 690 ([M-C H3]; +), m/z 
674 ([M-C H Oj+), m /z 544 ([M-{CsHIJ + TMSOH}]+ ) , m /z 508 
([M-C sH2FsOj+), and m /z 41 8 ([M-{C 7H2FsO '+ TMSO H}J+). 
Time Course of Mediator Release In 2 initial experim ents 
the effect o f ovalbumin over the concentration range o f 0. 1-1000 
J.L g/ml on the release of PGD2 was inves tiga ted. Maximal release 
of PGD 2 was obtained at 10 J.L g/ ml ovalbumin w ith no furth er 
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Figure 1. Immunochromatogram is shown for the PGD2 radioim mu-
noassay of 30-s fractions of HPLC efHuent from the Sep-Pak extracts of 
5-ml supernatant samples from anti gen-challenged skin (50 /Lg/ml oval-
bumin for 10 min) containing about 100 ng PGD2 as measured by 
radioimmunoassay. The column was eluted with l-chlorobutane: 
ace tonitrile:methanol:acetic acid , 60:40:3:0.3 by volume at 1. 5 mllmin. 
The immunochromatogram is the mean of duplica te sa mples. The arrolVS 
mark the retention times of: (1) arachidonic acid and hydroxyeicosate-
traenoic acids (HETEs); (2) 13,14-dihydro-15-keto-PGE2; (3) PGD2; (4) 
13,1 4-dihydro-15-keto-PGF2a ; (5) thromboxane B 2; (6) PGE2; (7) 6-oxo-
PGFlo. The retention time of PGF2a was 8.5 min (not shown). 
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Figure 2. Time course of (a) PGD2, (b) histam ine, and (e) PGE2 release 
fro m sensitized skin slices incubated with (0 --- 0 ) or wi thout 
(e ---- e ) ovalbumin antigen (50 J-Lg/ ml ). The results are means of 
duplicate sam ples from 2 separate experimcnts. The maximum releases 
of PGD2 and PGE2 after subtraction of the 5-min preincubation levels in 
the 2 experiments were 3 17 and 92 ng PGD2/g dry weight of skin and 
175 and 81 ng PGE2/g dry weight of skin . Max imum histamine releases 
were 50.2% and 39.4%. 
increase at concentratio ns up to 1000 J-Lg/ml. Histamin e release 
showed a similar pat tern except that m aximal release was obtained 
at 50 J-Lg/ml. Therefore, in subsequent experiments 50 J-Lg/ml w as 
chosen as th e antigen concentration . T he time course of PGD2, 
PGE2, and histamin e release w as investiga ted at intervals from 
0.5 to 40 min after antigen challen ge. T he release of PGDz was 
detectable at 2 min after an tigen challenge and rose to a m aximum 
at abou t I S min in 2 ex perim ents (Fig 20). Prostaglandin Dz was 
also synthes ized in the absence of ovalbumin , but at a mu ch lower 
rate th an with antigen. At 10 min there was a m ea n II-fold 
stim ulation o f PGDz release b y antigen compared to control. 
Antigen-evo ked histam ine release w as m o re rapid than PGD2 
release (Fig 20), being about 30% of m ax imum at 2 min. T he 
time taken to reach 50% of m ax imum release was about 4 min 
ANA PHYLACTIC PGD, RELEASE BY G UIN EA PI G SKIN 117 
fo r hista mine co mpared to abo ut 7 min fo r PGDz. Spontaneo us 
hista min e release from un challenged skin slices was negli g ible 
over the 40-min incubation period. Pros taglandin E2 was prod uced 
at a slig htl y in creased rate in the presence of anti gen co mpared 
to spontaneous release (Fig 2c), but this was sma ll co mpared to 
the stimulation o f PGDz release by anti gen. 
The Magnitude of Immunologic Release ofPGDz and His-
tan"line In 11 ex perim ents (Ta ble I) there was a 6- fo ld increase 
in the m ea n level of PGDz release from anti gen-challenged skin 
(399 ± 53 ng/g) compared to un challenged contro l (67 ± 19 ng/g 
dry weight o f skin). In contrast th e re lease of PGEz increased by 
onl y 27% under the sa me condit io ns. O n antigen challenge there 
was a m ea n 50.8% histamine rel ease compared to 3.6% without 
antigen . The average m o lar .ratio of histamine: PGDz released by 
anti gen in the 11 ex perim ents was 27 :1 . In contras t to the results 
usin g skin fro m sensitized an im als, no increase in PGDz was 
o bse rved w hen ski n slices from un sensiti zed animals were chal-
len ged w ith 50 ILg/ml o va lbumin for 15 m in in 2 ex perim ents. 
T he m ea n release of PGD z w ith antigen was 29 ng/g compared 
to 35 ng/g dr y w eight o f skin for th e un challenged contro l. There 
was no detectable hista min e release w ith o r w itho ut anti gen . 
The Nonimmunologic Release of PGD2 b y Compound 
48/80 T he results of 5 expcrimenrs in w hich skin slices fro m 
sensiti zed g uinea pigs were incubated w ith 50 ILg / mJ co mpou nd 
48/ 80 and /o r ova lbumin are shown in T able II. Compo und 48/80 
caused an average net 21 .6% release of his tamine from skin slices 
and sig nifi cantl y increased th e generati on of PGDz b y about 4-
fo ld , but it had no effect on PGEz synthesis. C hallenge with 
ova lbumin alone gave an approximately 6-fold increase in PGDz 
and also increased the release of PGE2 by 3 1 % above the spon-
taneous le vel, althou g h in this gro up of expe rim ents the increase 
in PGEz was no t sig nifi cant at the 5% level. C hall enge w ith 
co mpound 48/80 and ova lbumin together was no t add iti ve und er 
these co ndit io ns, but ga ve va lues fo r hista mine and PG D 2 release 
approxi m ately mid way between the va lues fo r ovalbumin and 
compo und 48/80 alone. 
Effect of Indomethacin The stimu lated release ofPGDz from 
sensitized skin fo ll owin g antigen chall enge was almost co mpletely 
abolished by 14 ILm indo m ethacin (Ta ble III ) w hi ch gave on ly a 
sma ll red uction in hi stamine release. T he synth es is of PGEz with 
and witho ut antigen and the spontaneous release of PG Dz were 
also inhibited , altho ugh not to the sa m e degree. 
D ISC U SS IO N 
We have dem onstrated th at skin slices from ova lbumin-sensitized 
guinea pigs ca n synthesize and release PGDz w hen incubated in 
vitro. When sli ces were challenged wi th 50 ILg/ ml ova lbumin the 
release of PG Dz was increased 6-fold , acco m panied by the release 
Table I. Release of PGDz, PGE2, and Hi stamin e frolll 
Sensitized G uin ea Pig Skin Followin g Anti gen C hallenge 
Med iator 
PGD2 (ng/g dry wt of 
skin) 
PGEz (ng/g dry wt of 
skin) 
Histamine" (% release) 
Spontaneo Lls 
Release 
67 :±: 19 
67 :±: 9 
3.6 :±: 2.5 
Release in the Presence 
of Ovalbumin 
(50 J-Lg/ ml ) p" 
399 :±: 53 < 0.00 1 
85 ± 7 = 0.02 
50.8 ± 2.5 < 0.00 1 
T he samples w ere prc incubatcd at 37°C for 5 min . Ova lbum in antigen o r co nt"ro l 
buffer were th en added a11d lh e in cuba ti o n co nt inued for a further 10 mill . The 
5-rnin p rc in cub"io n levels o f PCD, and PGE, (129 ± 23 and 126 ± 14 ng/g dry 
wcig ht of skin . respectivel y) were subtracted fro m the le vels afte r IS-min incuba tion 
to g ive IIct rcic:lscs fo r 10 min wi th o r w itho llt o va lbu m in. All va lu es we re expressed 
as means ± SEM (n = II ). 
"Paired {-tcs t. 
hMc.:a n histamine co ntent o f sk in :lfrcr 5- rnin prcin cub:ui o l1 was 5.99 ± 0.44 
/-Lg/g dr y weig ht of sk in . 
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Table II. Com parison of the Effects of Compound 48/80 and Antigen, Alone and in Combination, on the Release of PGDz, 
PGEz, and Histamine from Sensitized G uinea Pig Skin 
Ovalb umin and 
Compound 48/80 Ova lbum in Compo und 48/80 
Mediator Spontaneo us (5O /Lg/ m l) (50 /Lg/m l) (both 50 /Lg/ml ) 
PGDz (ng/g dry wt 89 <±: 30 340 ± 86" 512 ± 58/' 455 ± 39b 
of skin) 
PGEz (ng/g dry wt 75 ± 7 78 ± 11 98 ± 8 93 ± 18 
of skin) 
Hista mine (% release) 7. 1 ± 4.5 28 .7 ± 3.4" 52.6 ± 3.5" 42.4 ± 1. 3" 
The ,"mples were incubated for 10 min at 37°C w ith or w itho ut co mpound 48/80 and/ or ova lbumi n after an ini tia l preincuba tio n period o f 5 min . Mediato r release WlS 
measured as described in Table I. All values arc exp ressed as means ± SEM (11 = 5). St:uisci ca l signi fi cance or release co mpared to respecti ve spontaneous release was 
determined by the paired I-test. 
"0.05 > l' > 0.0 1. 
'1' < 0.01. 
of about 50% of the skin hi sta mine conten t. T he identity of the 
PGDz was supported by HPLC and confirmed by GC-MS . Pros-
tagla ndins are synthesized and released by the generating cells in 
response to sti muli that ca use the liberation of arachidoni c acid 
wh ich is a substrate for the cyclooxygenase pathway. Ruzicka 
and Prin tz have demonstrated that guin ea pig skin ho mogenates 
generate PGD2 as the major cyclooxygenase product via a specific 
PGDz isomerase 1'1 0]. In our study, using in tact skin s li ces, simi lar 
amounts of PG Dz and PGEz were generated spontaneously. 
T he large increase in PGD2, but not PGE2, production follow-
in g hi stamine release induced by ova lbumin anti gen implies that 
the mast cell may be the so urce of this stimu lated PGD2 since 
purified rat and human mast cells preferentially generate PGDz 
[1,1 1]. The ti m e course of PGDz release was simi lar to although 
slightly slower than that of histamine, w hi ch is consistent with 
hi stamine as a prefo rmed mediator w hi ch ca n be secreted rapidly 
by m ast cells in response to the appropriate stimulus, w hereas 
PGDz has to be newly' synthesized and released [2]. However, 
the spontaneous release of PGD2 may come from a variety of cell 
types other than mast cells including the epidermis [1 01. 
T he PGEz that was released throu ghout the incubation period 
was on ly s li ghtly stimulated by ova lbu mi n chall enge. The cell ular 
source of thi s relatively small amoun t of antigen-specific PGEz is 
uncertain. There is no evidence that purifi ed rat mast cells generate 
signi ficant amounts ofPGEz [1] . It seems un likely that other cells 
within the skin slices synthesize PGEz secondari ly in res ponse to 
the action of released mast cell mediators such as histamine since 
there was no PGEz release from sli ces incubated with compound 
48/80. Compound 48/80 at 50 J.Lg/ml induced the release of both 
PGD2 and hista mine in proportions similar to ovalbumin chal-
lenge but was not as effective as 50 J.Lg/ ml ovalbum.in in eliciting 
release of these mediators fro m sk in of sensitized anim als. 
T he relea se of histamine and PGDz occurs rapidly after antigen 
challenge of the skin sli ces, impl yi ng a close linkage between the 
two processes . H owever, our obse rvation that indometha cin sup-
pressed the stimulated synthesis of PGDz by antigen, but only 
marg inall y reduced hi stam ine release, suggests that histamine re-
lease is not dependent on cyclooxygenase activity as has been 
found by other autho rs [1 2, 13J. The signifi cance of the release of 
PGDz from skin in immediate allergic reactions is at present spec-
ulative. Flower and his co ll eagues [2J found that intraderm al in-
jection of submicrogram doses of PGDz into the forearm of hu-
mans ga ve a dose-related erythema w hich persisted for up to 6 
h , but PGDz was less potent as a vasod ilator than PGE2. However, 
very low concentrations of PGD2 potentiated the increase in vas-
cu lar permcability induced by histamine in rat skin by 100% . 
Prostaglandin Dz also potentiated ca rrageenin edem a and hyper-
algesia in thi s species. Ou r resul ts in the guin ea pig gave an average 
molar ratio of 27:1 of hista mine to PGDz releas,ed fo ll ow in g an-
tigen challenge, w hi ch suggests th at PGD2 is not as important as 
hista mine in its direct inflam matory effects but could still have 
an important potentiating role in sk in . T he possibility that PGDz 
could ampli fy the vasoactive effccts of histamine and other me-
diators in hu man skin is currentl y being explo red. 
Prostag landins D z and histamine have recently been shown to 
be elevated in venous blood drainin g the co ld-challenged arm in 
cold urti caria, w here mast cell degra nuation is probab ly involved 
[1 4J. It is also of interest that ev idence of in creased PGDz pro-
du ction has been reported in patients w ith systemi c mastocytosis 
115] , a conditi on in which cutaneous Aushin g and whealing are 
prominent clini cal features. We have reported in creased PGDz 
concentrations in inflam m atory exud ate from UV -irrad iated skin 
in humans f7 ,16]. Measurement of PGD2 in blood and skin ex-
udate in other infl ammato ry lesions of the skin in w hich mast 
cells arc thought to be in volved is an important subject for future 
study. 
Table III. Effect of Indometh acin on the Release of PGDz, PGE2 , and Histamine from Sensiti zed G uin ea Pig Skin 
PGDz (ng/g dry wt 
of skin) 
PGE2 (ng/g dry wt 
of skin) 
Hista mine (% release) 
M ed iator Release 
Spontaneous 
Without With 
Indo methacin Indomethacin 
50 28 
80 32 
0 1. 5 
In the Presence o f Ova lbumin (50 
/Lg/ 111 I) 
Without With 
Indomethacin Indomethacin 
169 12 
86 22 
52.7 44.0 
T he samples were incubated for 10 min at 37°C with or without ova1blllTJ'in after an initi al preincubation period of 5 min . In the sa mples containing indomethacin (14 
1-'111) it was add ed at the beginning of th e 5-l11 ill preincubation. Mediator rdease was measured as described in Ta ble I. All va lu es arc means of2 experiments. 
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